---
title: "Alto Neuroscience, Inc. (ANRO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ANRO.US.md"
symbol: "ANRO.US"
name: "Alto Neuroscience, Inc."
industry: "制藥"
---

# Alto Neuroscience, Inc. (ANRO.US)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 美股市場 |
| Website | [www.altoneuroscience.com](https://www.altoneuroscience.com) |

## Company Profile

Alto Neuroscience, Inc. 是一家在美國運營的臨床階段生物制藥公司。該公司的產品管線包括 ALTO-100，目前正在進行針對雙相抑鬱症（BPD）患者的 2b 期臨床試驗。它還開發了 ALTO-300，這是一種具有抗抑鬱特性的低分子褪黑激素激動劑和 5-羥色胺拮抗劑，目前正在進行針對重度抑鬱症（MDD）患者的 2b 期臨床試驗；ALTO-101，一種新型低分子磷酸二酯酶 4 抑制劑，目前正在進行針對與精神分裂症相關的認知障礙的 2 期概念驗證（POC）試驗；ALTO-203，一種新型低分子組胺 H3 受體反向激動劑，目前正在進行針對 MDD 和更高水平快感缺失的患者的 2 期...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.64 | 179/257 | - | - | - |
| PB | 5.38 | 141/257 | 4.09 | 0.79 | 0.46 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 9 | 90% |
| Overweight | 0 | 0% |
| Hold | 1 | 10% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 19.62 |
| Highest Target | 50.00 |
| Lowest Target | 13.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ANRO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ANRO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ANRO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.